Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis. by B-Lajoie, Marie-Renée et al.
Clinical Infectious Diseases
M A J O R A R T I C L E
HIV/AIDS
Incidence and Prevalence of Opportunistic and Other
Infections and the Impact of Antiretroviral Therapy
Among HIV-infected Children in Low- and Middle-
income Countries: A Systematic Review and Meta-analysis
Marie-Renée B-Lajoie,1 Olivier Drouin,2 Gillian Bartlett,1 Quynh Nguyen,1 Andrea Low,3 Georgios Gavriilidis,4 Philippa Easterbrook,5 and Lulu Muhe4
Departments of 1Family Medicine, and 2Paediatrics, McGill University, Montreal, Canada; 3Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and
Tropical Medicine, United Kingdom; Departments of 4Maternal, Child and Adolescent Health, and 5HIV/AIDS, World Health Organization, Geneva, Switzerland
(See the Major Article by Low et al on pages 1595–1603.)
Background. We conducted a systematic review and meta-analysis to evaluate the incidence and prevalence of 14 opportunistic
infections (OIs) and other infections as well as the impact of antiretroviral therapy (ART) among human immunodeﬁciency virus
(HIV)–infected children (aged <18 years) in low- and middle-income countries (LMICs), to understand regional burden of disease,
and inform delivery of HIV services.
Methods. Eligible studies described the incidence of OIs and other infections in ART-naive and -exposed children from January
1990 to November 2013, using Medline, Global Health, Embase, Cumulative Index to Nursing and Allied Health Literature, Web of
Knowledge, and Literatura Latino Americana em Ciências da Saúde databases. Summary incident risk (IR) and prevalent risk for
each OI in ART-naive and ART-exposed children were calculated, and unadjusted odds ratios calculated for impact of ART. The
number of OI cases and associated costs averted were estimated using the AIDS impact model.
Results. Weidentiﬁed 4542 citations, and88 studieswere included, comprising 55 679HIV-infected children. Bacterial pneumonia and
tuberculosiswere themost common incident andprevalent infections inbothART-naive andART-exposed children.Therewas a signiﬁcant
reduction in IRwithARTfor themajorityofOIs.Therewas a smaller impact onbacterial sepsis andpneumonia, andan increaseobserved for
varicella zoster. ART initiation based on 2010WorldHealthOrganization guidelines criteria for ART initiation in children was estimated to
potentially avert >161 000 OIs (2013 UNAIDS data) with estimated cost savings of at least US$17 million per year.
Conclusions. There is a decrease in the risk ofmostOIs withARTuse inHIV-infected children in LMICs, and estimated large potential
cost savings in OIs averted with ART use, although there are greater uncertainties in pediatric data compared with that of adults.
Keywords. pediatrics; opportunistic infections; HIV; low- and middle-income countries.
In 2014, 2.6 million children aged <15 years worldwide were liv-
ing with human immunodeﬁciency virus (HIV), of whom 88%
lived in sub-Saharan Africa [1]. The same year, there were
220 000 new infections and 150 000 deaths among children, of
which the majority can be attributed to opportunistic infections
(OIs) [1, 2]. Although there has been a 60% decline in new pedi-
atric HIV infections since 2000, and a 42% decline in HIV-related
deaths, scale-up of antiretroviral therapy (ART) has been much
less successful in children compared with adults [1, 3, 4]. As of
2014, only one-third of children <15 years of age in need of treat-
ment were receiving it, compared with two-thirds of adults [5].
Large multicenter cohort studies among HIV-infected chil-
dren in high-income countries (HICs) [6–8] have demonstrated
a decrease in incidence and prevalence of most OIs following
ART introduction [9–11], but the effect of ART in low- and
middle-income countries (LMICs) has generally been less well
documented.
Reliable data on the relative burden of different OIs in children
are important for planning delivery of HIV services, which in-
cludes drug procurement, use of prophylaxis, and provision of ap-
propriate diagnostic capacity. Our objective was to undertake a
comprehensive systematic review and meta-analysis to estimate
the incidence and prevalence of key OIs and other infections in
HIV-infected children, both before and after the initiation of
ART in LMICs across 3 geographic regions (Asia, sub-Saharan
Africa, and Latin America), and to evaluate the magnitude of ef-
fect of ART on these infections and potential costs averted.
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METHODS
Search Strategy and Selection Criteria
A systematic review of the literature was performed using the
Medline, Embase, Global Health, Cumulative Index to Nursing
and Allied Health Literature, Literatura Latino Americana em
Ciências da Saúde, and Web of Science databases, and the Co-
chrane Library of Systematic Reviews from January 1990 to No-
vember 2013, published in English, French, Spanish, and
Portuguese (see Supplementary Appendix 1 for the search strat-
egy used). Eligible studies reported the incidence and/or preva-
lence in children aged <18 years in LMICs (as deﬁned by the
2010 World Bank classiﬁcation) [12] of 14 OIs and other
infections, including cryptococcal meningitis; Pneumocystis
pneumonia; candidiasis (oral and esophageal combined); cyto-
megalovirus retinitis; varicella zoster virus (VZV); herpes sim-
plex virus stomatitis; Kaposi sarcoma; cerebral toxoplasmosis;
cryptosporidial diarrhea; Mycobacterium tuberculosis (hereafter
“tuberculosis”), which was further subdivided into pulmonary tu-
berculosis (PTB), extrapulmonary tuberculosis, (EPTB), or all
types of tuberculosis combined (cTB); and bacterial infections
(bacterial pneumonia, bacterial meningitis, isolated bacteremia,
and sepsis). LMICs were divided into 3 regions for the purpose
of the analysis: sub-Saharan Africa, Latin America and the Carib-
bean, and Asia. Eligible study designs were cross-sectional, pro-
spective and retrospective cohort studies, and randomized
controlled trials (RCTs). This review used Meta-analysis of Ob-
servational Studies in Epidemiology and Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines for
systematic reviews [13, 14].
Two independent reviewers (M.-R. B.-L. and O. D.) screened
abstracts and titles to identify potentially relevant articles. Eligi-
ble studies included >50 HIV-infected children, and provided
data from which a cumulative incident risk (IR) of 1 or more
of 14 different OIs or infections could be calculated (ie, number
of episodes or events as well as a denominator of number of
children in the study). Twenty-four authors were contacted to
provide additional missing data, and 7 responded. The follow-
ing data were extracted for each study: study design, duration of
follow-up, mean/median age or age groups included, ART sta-
tus (naive or ART exposed including time on ART), use of co-
trimoxazole (CTX) prophylaxis, baseline CD4 cell counts, study
setting (urban, rural, mix), and diagnostic methods. See Supple-
mentary Appendix 2 for further details on methodology.
Study Deﬁnitions
The ART status of the study population was categorized by study
as either “ART naive” (studies conducted prior to the availability
of ART, or where <10% of the population were ART exposed) or
“ART exposed” (studies where >80% of the population were on
ART). Studies where the proportion on ART was >10% but
<80%, or which did not provide data on ART use, were excluded.
No distinction was made according to ART regimens, as there
was heterogeneity over time and by geographic region. Few stud-
ies reported duration of time on ART, but this was extracted
where available (see Supplementary Appendix 2 for further def-
initions). For each study, 2 investigators independently rated
quality of diagnostic approaches for each OI.
Meta-analysis
The cumulative IR for individual OIs for each study in both
ART-naive and ART-exposed children were estimated based
on the cumulative number of children who developed the spe-
ciﬁc OI divided by the number of children at risk during the
follow-up period, and are presented as a percentage. This ap-
proach was used because of inconsistency in incidence report-
ing across studies, with few reporting annual incidence rates per
children-years. Prevalent rate or risk (PR) was deﬁned as the
number of children with the OI or other infections divided by
the total number of children in the cross-sectional sample.
Ninety-ﬁve percent conﬁdence intervals (CIs) for both IR and
PR were extracted from the papers if available or calculated
from the raw data where possible.
Summary IR and PR were calculated by stabilizing the varianc-
es of raw percentages using a Tukey-Freeman arcsine square root
transformation. Summary risks for individual OIs were then
obtained across studies using a random-effects meta-analysis to
adjust for the wide variability between studies [15, 16]. Heteroge-
neity between studies was evaluated using I2 and the P value (Co-
chran Q statistic) for heterogeneity. A high I2 index (75%)
indicates high heterogeneity, whereas a low index (<25%) indi-
cates variability in risk estimates due to within-study variability
and therefore low heterogeneity. R software version 2.14.0 was
used to perform the analysis. Meta-regression analyses could
not be completed because both the number of studies and sample
size were limited. The unadjusted odds ratio (OR) was used as a
crude estimate for the effect of ART, as there were insufﬁcient data
to adjust for confounders. The OR was calculated by applying the
calculated IR and PR obtained by random-effects analysis to the
absolute number of children affected in the included studies.
OI Cases Averted by the Use of ART
The estimated numbers of HIV-infected children in need of
ART were based on the 2010 World Health Organization
(WHO) guidelines criteria for ART initiation [17] as we had
the most complete dataset for these criteria, than for the
WHO 2013 or 2015 criteria, (ie, all HIV-positive children <2
years of age, those aged 2–4 years with a CD4 percentage
<25%, and those aged 5–14 years with a CD4 count <350
cells/uL), for 156 LMICs using the 2013 Joint United Nations
Programme on HIV/AIDS (UNAIDS) global country estimates
for the number of HIV-infected children generated using
the AIDS impact model (AIM) [18, 19]. For each country,
the AIM model has been used to estimate incidence trends by
ﬁtting smooth curves to surveillance and survey data. New in-
fections are followed over time as they progress from higher to
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lower CD4 counts. The number of OI cases averted was
estimated by applying risk difference on speciﬁc OI incidence
rates in ART-exposed, relative to ART-naive children to the es-
timated number of children at risk of developing OIs in the 3
geographic regions. The annual cost averted per OI was calcu-
lated for 6 OIs (Pneumocystis pneumonia, cryptococcal menin-
gitis, Cryptosporidium, herpes simplex virus, candidiasis, and
tuberculosis (PTB and EPTB) where there was both evidence
of a decrease in incidence with ART, and where the cost of treat-
ing the OI case was known [20], by multiplying the number of
OI cases averted by the cost of OI treatment per case. There were
insufﬁcient data on treatment costs to include several important
infections such as bacterial pneumonia. The 95% CI uncertainty
ranges are based on 1000 Monte Carlo simulations assuming
normal distributions of incidence risk.
RESULTS
The search strategy identiﬁed 4542 citations with an additional 29
identiﬁed through cross-referencing. Of these 4571 citations, 589
potentially relevant full-text articles were screened and 88 studies
met inclusion criteria for eligibility in quantitative analysis: 7 had
both prevalence and incidence data, 53 had prevalence data, and
28 had incidence data (Figure 1). Table 1 and Supplementary Ap-
pendix 3 summarize the characteristics of included incidence and
prevalence studies, respectively. Supplementary Appendices 6 and
7 include all references to included studies, as well as geographic
location of included studies.
Incidence of OIs and Other Infections
The 35 studies of incidence (30 cohorts and 5 RCTs) involved
23 266 children. Twenty studies were based in sub-Saharan
Africa (n = 13 547 children), 9 in Asia (n = 2207), and 5 in
Latin America and the Caribbean (n = 3293). One study was
based in multiple sites in LMICs (n = 3946). All studies were
outpatient based. The majority of children had vertically ac-
quired HIV infection; of 19 (54%) for whom age was reported,
the median age at study report was 41 months (range, 3–156
months). Eleven studies (31%) used appropriate diagnostic
methods (for deﬁnitions, see Supplementary Appendices 2
Figure 1. Flowchart of study selection for incidence and prevalence of opportunistic infections in resource-limited settings. Abbreviations: CINAHL, Cumulative Index to
Nursing and Allied Health Literature; HIC, high-income country; HIV, human immunodeficiency virus; LILACS, Literatura Latino Americana em Ciências da Saúde.
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Table 1. Characteristics of Included Studies—Incidence of Opportunistic Infections and Other Infections, by Region








Asia 1 cohort 329 54 (1) 0.60–180 (1) 1 (100)
LAC 3 cohorts 2414 (110–1859) NA NA 0 (0)
Pneumocystis pneumonia
SSA 1 RCT, 1 cohort 632 (98–534) 53 (1) NA 0 (0)
Asia 4 cohorts 1080 (124–317) 62 (2) 43–96 (2) 1 (25)
LAC 4 cohorts 2700 (110–1859) 66 (2) 23–159 (2) 0 (0)
Oral candidiasis
SSA 2 cohorts 244 (54–190) NA NA 0 (0)
Asia 4 cohorts 1033 (102–329) 54 (1) 0.60–180 (2) 3 (75)
LAC 2 cohorts 841 (110–731) 66 (2) 23–159 (2) 0 (0)
Esophageal candidiasis
SSA 1 cohort 1206 NA NA 0 (0)
Asia 3 cohorts 671 (149–317) 64 (2) 22–138 (2) 2 (67)
LAC 4 cohorts 3145 (110–1859) 66 (2) 23–159 (2) 0 (0)
CMV retinitis
Asia 1 cohort 329 54 (1) 0.60–180 (1) 0 (0)
LAC 2 cohorts 953 (222–731) 7, 5 (1) NA 1 (50)
Varicella zoster virus
Asia 4 cohorts 815 (67–329) 52 (2) 0.65–180 (2) 0 (0)
LAC 2 cohorts 1176 (158–731) 60 (2) 36–108 (1) 0 (0)
Herpes simplex virus
SSA 1 cohort 190 NA NA 0 (0)
Asia 2 cohorts 997 (329–668) 54 (1) 0.60–180 (1) 0 (0)
LAC 4 cohorts 3145 (110–1859) 66 (2) 23–159 (2) 0 (0)
Kaposi sarcoma
LAC 1 cohort 1859 NA NA 0 (0)
Cerebral toxoplasmosis
Asia 1 cohort 329 132 (1) 132–180 (1) 1 (100)
LAC 4 cohorts 3145 (110–1859) 64 (3) 24–138 (1) 0 (0)
Cryptosporidium diarrhea
SSA 1 cohort 54 13 (1) NA 1 (100)
Asia 1 cohort 329 54 (1) 0.6–180 (1) 2 (100)
LAC 3 cohorts 3010 (420–1859) 60 (1) 36–108 (1) 0 (0)
Mycobacterium tuberculosis
SSA 5 RCT, 11 cohorts 13 459 (38–6301) 43 (12) 26–75 (9) 11 (69)
Asia 6 cohorts 1358 (102–329) 60 (3) 15–152 (3) 3 (50)
LAC 3 cohorts 1212 (110–731) 66 (2) 23–159 (2) 0 (0)
Pulmonary tuberculosis
SSA 4 RCT, 5 cohorts 4234 (131–1206) 52 (6) 30–80 (4) 7 (78)
Asia 3 cohorts 931 (285–329) 54 (1) 0.60–180 (1) 3 (100)
LAC 2 cohorts 481 (110–371) 72 (1) 11–210 (1) 0 (0)
Extrapulmonary tuberculosis
SSA 1 RCT, 2 cohorts 1119 (210–635) 40 (2) 26–59 (2) 2 (68)
Asia 4 cohorts 1080 (149–329) 65 (2) 32–138 (2) 3 (75)
LAC 1 cohort 110 72 (1) 11–210 (1) 0 (0)
Bacterial pneumonia
SSA 1 RCT, 7 cohorts 7421 (54–5752) 63 (3) 16–136 (2) 1 (13)
Asia 3 cohorts 294 (102–317) NA NA 0 (0)
LAC 2 cohorts 445–731 60 (1) 36–108 (1) 0 (0)
Bacterial meningitis
SSA 1 RCT, 1 cohort 939 (405–534) 53 (2) 23–90 (1) 0 (0)
Asia 1 cohort 192 NA NA 0 (0)
LAC 2 cohorts 1176 (445–731) 60 (1) 36–108 (1) 0 (0)
Isolated bacteremia
LAC 1 cohort 731 60 (1) 36–108 (1) 0 (0)
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Table 1 continued.








SSA 1 RCT, 1 cohort 6286 53 (1) NA 1 (50)
Asia 2 cohorts 397 77 (1) 43–96 (1) 0 (0)
LAC 1 cohort 445 NA NA 0 (0)
Abbreviations: CMV, cytomegalovirus; IQR, interquartile range; LAC, Latin America and the Caribbean; NA, data not available; RCT, randomized controlled trial; SSA, sub-Saharan Africa.
a Diagnosis confirmation is as follows: cryptococcal meningitis (India ink stain of cerebrospinal fluid [CSF]), cerebral toxoplasmosis (immunoglobulin M–positive serology), Pneumocystis
pneumonia (bronchoalveolar lavage and stain), bacterial pneumonia (suggestive chest radiograph), bacterial meningitis (CSF culture), isolated bacteremia or sepsis (blood culture), herpes
simplex virus stomatitis, varicella zoster virus (viral culture), cytomegalovirus retinitis (viral culture), oral and esophageal candidiasis (microscopy or fungal culture), Kaposi sarcoma (biopsy
and histology), cryptosporidial diarrhea (modified acid-fast stool stain), and pulmonary tuberculosis (mycobacterial sputum culture) and extrapulmonary tuberculosis (culture).
Figure 2. Summary incident risk by region for antiretroviral therapy (ART)–naive (A) and ART-exposed (B) patients. Abbreviations: CMV, cytomegalovirus; LAC, Latin America
and the Caribbean; PCP, Pneumocystis pneumonia; SSA, sub-Saharan Africa; TB, tuberculosis.
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and 3 or Table 1), 16 reported use of CTX prophylaxis (46%), 11
baseline CD4 count (31%), 9 WHO stage (26%), 14 duration of
time on ART (40%), and 3 age at ART initiation (9%).
Table 2 and Figure 2 shows the incidence of 14 OIs and re-
lated infections in ART-naive and -exposed HIV-infected chil-
dren. The most common infections in ART-naive children were
bacterial pneumonia (25.01% [95% CI, 14.50%–37.91%]; n = 9),
cTB (12.36% [95% CI, 7.95%–17.59%]; n = 17), PTB (9.78%
[95% CI, 5.37%–15.34%]; n = 10), oral and esophageal candidi-
asis (8.29% [95% CI, 3.75%–14.39%]; n = 8), and EPTB (7.26%
[95% CI, 3.00%–13.18%]; n = 4). A similar proﬁle was observed
in ART-exposed children, with bacterial pneumonia (22.11%
[95% CI, 11.58%–34.89%]; n = 7), cTB type (8.84% [95% CI,
5.21%–13.31%]; n = 20), and VZV (8.40% [95% CI, 4.78%–
12.91%]; n = 5) being the most common infections. A complete
summary of all OIs with a regional overview is available in Sup-
plementary Appendices 3 and 4. Tuberculosis was the only OI
for which each region had a large enough number of studies re-
porting incidence to allow for a meaningful comparison by geo-
graphic region (Table 3).
Prevalence of OIs and Other Infections
The 60 prevalence studies (44 cross-sectional studies, 15 co-
horts, and 1 RCT) involved 36 357 children, with data from
47 studies in sub-Saharan Africa, 9 in Asia, and 4 in Latin
America and the Caribbean (Supplementary Appendix 3 pro-
vides information on included prevalence studies). The median
age was 56 months (range, 2–158 months), for the 26 studies
where age was reported. Nine studies used appropriate diagnos-
tic approaches. Eight studies reported use of CTX prophylaxis
(13%), 22 reported baseline CD4 count (37%), 9 reportedWHO
stage (15%), 6 reported time on ART (10%), and 8 reported the
age at ART onset (13%), and as such adjustment for these var-
iables in subgroup analyses was not possible.
Table 4 shows similar ﬁndings to those observed for the IR.
The most prevalent infections were bacterial pneumonia
(32.51% [95% CI, 21.96%–44.04%]; n = 21), oral and esophage-
al candidiasis (24.77% [95% CI, 19.31%–30.67%]; n = 26), and
Table 2. Estimated Summary Incident Risk for Opportunistic Infections and Other Infections, by Antiretroviral Status
Opportunistic Infection
Summary of Incident Risk, % (95% CI) (No. of Studies)
Unadjusted Odds
Ratio (95% CI)aART Naive ART Exposed
Cryptococcus neoformans meningitis 0.55 (.10–1.36) (3) 0.25 (.04–.66) (4) 0.42 (.11–1.83)
Pneumocystis pneumonia 3.48 (1.23–6.82) (7) 2.49 (.34–6.54) (7) 0.71 (.50–1.01)
Oral and esophageal candidiasis 8.29 (3.75–14.39) (8) 3.20 (1.71–5.15) (8) 0.37 (.29–.46)
CMV retinitis 0.82 (.15–2.04) (2) 0.85 (.01–3.69) (2) 0.99 (.24–4.71)
Varicella zoster virus 4.69 (2.44–7.62) (3) 8.40 (4.78–12.91) (5) 1.88 (1.23–2.87)
Herpes simplex 1.59 (.43–3.48) (5) 1.33 (.23–3.32) (5) 0.86 (.53–1.41)
Kaposi sarcoma NA 0.06 (.01–.14) (2) NA
Cerebral toxoplasmosis 3.06 (.85–6.59) (3) 0.72 (.15–1.71) (5) 0.23 (.13–.43)
Cryptosporidium diarrhea 2.92 (.00–10.97) (3) 0.31 (.01–1.06) (7) 0.10 (.05–.22)
Mycobacterium tuberculosis (unspecified types) 12.36 (7.95–17.59) (15) 8.84 (5.21–13.31) (18) 0.69 (.63–.75)
Pulmonary tuberculosis 9.78 (5.37–15.34) (10) 3.99 (2.66–5.56) (9) 0.38 (.32–.46)
Extrapulmonary tuberculosis 7.26 (3.00–13.18) (4) 1.12 (.40–2.18) (6) 0.15 (.10–.21)
Bacterial pneumonia 25.01 (14.50–37.91) (9) 22.11 (11.58–34.89) (7) 0.85 (.78–.92)
Isolated bacteremia NA 7.50 (.25–1.50) (1) NA
Bacterial meningitis 0.95 (.48–1.56) (3) 0.80 (.36–1.42) (3) 0.85 (.33–2.12)
Bacterial sepsis 3.95 (1.46–7.58) (4) 2.39 (.00–9.19) (4) 0.59 (.47–.75)
Abbreviations: ART, antiretroviral therapy (combines both specified and unspecified); CI, confidence interval; CMV, cytomegalovirus; NA, numbers insufficient to perform analysis.
a Reference is naive population.
Table 3. Estimated Summary Incident Risk for Mycobacterium
tuberculosis, by Regiona
Opportunistic Infection
Summary of Incident Risk, % (95% CI) (No. of
Studies)




12.36 (7.95–17.59) (15) 8.84 (5.21–13.31) (18)
Sub-Saharan Africa 10.58 (5.89–16.44) (9) 9.52 (5.00–15.29) (12)
Asia 23.10 (11.82–36.79) (4) 9.10 (.00–33.60) (4)
Latin America and
Caribbean
1.48 (.50–2.95) (2) 0.74 (.24–1.51) (2)
Pulmonary tuberculosis 9.78 (5.37–15.34) (10) 3.99 (2.66–5.56) (9)
Sub-Saharan Africa 8.27 (5.11–12.09) (5) 6.09 (2.40–11.33) (6)
Asia 18.60 (6.43–35.23) (3) 4.61 (2.18–7.89) (1)
Latin America 1.48 (.50–2.95) (2) 0.39 (.01–1.28) (1)
Extrapulmonary
tuberculosis
7.26 (3.00–13.18) (4) 1.12 (.40–2.18) (6)
Sub-Saharan Africa NA 2.49 (.04–8.53) (3)
Asia 10.27 (6.96–14.12) (3) 2.101 (.33–11.74) (2)
Latin America and
Caribbean
1.31 (.05–4.26) (1) NA
Abbreviations: ART, antiretroviral therapy (combines both specified and unspecified);
CI, confidence interval; NA, numbers insufficient to perform analysis.
a A study reporting data frommultiple international sites in low- andmiddle-income countries
is included in the pooled analysis but not the individual regional analysis, explaining the
missing study in the total number of studies compared to the regional analysis.
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bacteremia (23.18% [95% CI, 10.12%–39.62%]; n = 5). A com-
plete summary of all OIs with a regional overview is available in
Supplementary Appendices 3 and 4.
Impact of ART on Incidence
Tables 2 and 4 show, respectively, the IR and PR, as well as the
OR to quantify impact of ART. For IR, the OR ranged from 0.10
to 1.88, and the greatest (>80% reduction in risk) and most sta-
tistically signiﬁcant reductions were seen for Cryptosporidium
diarrhea (OR, 0.10 [95% CI, .05–.22]), cerebral toxoplasmosis
(OR, 0.23 [95% CI, .13–.43]), and EPTB (OR, 0.15 [95% CI,
.10–.21]). For all OIs except EPTB, however, the 95% CIs of
the IR in ART-naive and ART-exposed patients overlapped.
Based on the OR of prevalence, Cryptosporidium diarrhea
(OR, 0.03[95% CI, .00–.18]) and bacteremia (OR, 0.23 [95%
CI, .16–.33]) showed a substantial decrease in burden (≥
80%) with nonoverlapping CIs between ART-naive children
and ART-exposed children. All other OIs showed over-
lapping CIs in ART-naive compared with ART-exposed
children.
Table 4. Estimated Summary Prevalent Risk for Opportunistic Infections and Other Infections, by Antiretroviral Status
Opportunistic Infection
Summary of Prevalent Risk, % (95% CI) (No. of Studies)
Unadjusted Odds
Ratio (95% CI)aART Naive ART Exposed
Cryptococcus neoformans meningitis 3.98 (.89–9.13) (3) 16.65 (7.33–28.80) (1) 4.46 (1.45–13.44)
Pneumocystis pneumonia 7.40 (2.28–15.13) (9) 8.40 (.65–10.52) (1) 1.43 (.83–1.58)
Oral and esophageal candidiasis 24.77 (19.31–30.67) (26) 18.23 (5.84–35.49) (8) 0.68 (.57–0.80)
CMV retinitis 1.02 (.28–2.21) (3) 0.89 (.34–1.69) (1) 0.87 (.25–3.18)
Varicella zoster virus 5.33 (2.22–9.67) (7) 14.73 (4.25–30.05) (1) 3.12 (2.11–4.62)
Herpes simplex 3.23 (1.02–6.64) (2) 5.99 (.70–15.95) (3) 1.82 (.68–5.28)
Kaposi sarcoma 2.98 (1.15–5.61) (4) 4.18 (.76–10.18) (2) 1.55 (.39–5.17)
Cerebral toxoplasmosis 1.53 (.06–4.97) (1) 1.30 (.61–2.24) (1) 1.29 (.17–27.24)
Cryptosporidium diarrhea 4.98 (2.62–8.05) (3) 0.20 (.01–.65) (1) 0.03 (.00–.18)
Mycobacterium tuberculosis (unspecified types) 13.78 (11.26–16.51) (20) 7.53 (2.80–14.28) (3) 0.51 (.40–.64)
Sub-Saharan Africa 13.95 (9.86–18.62) (18) 15.86 (3.18–35.67) (2) . . .
Asia 38.19 (27.38–49.63) (1) NA . . .
Latin America 9.57 (4.47–17.40) (1) 8.89 (6.93–11.19) (1) . . .
Pulmonary tuberculosis 13.75 (8.12–20.58) (11) 8.95 (6.99–11.12) (1) 0.61 (.46–.82)
Extrapulmonary tuberculosis 5.97 (2.56–10.69) (9) NA NA
Bacterial pneumonia 32.51 (21.96–44.04) (21) 38.16 (12.79–67.66) (2) 1.28 (1.09–1.52)
Bacteremia 23.18 (10.12–39.62) (5) 6.57 (4.98–8.35) (3) 0.23 (.16–.33)
Bacterial meningitis 1.98 (1.08–3.16) (8) 4.16 (1.41–8.27) (2) 2.14 (1.24–3.69)
Bacterial sepsis 14.49 (7.66–23.05) (11) NA NA
Abbreviations: ART, antiretroviral therapy (combines both specified and unspecified); CI, confidence interval; CMV, cytomegalovirus; NA, numbers insufficient to perform analysis.
a Reference is naive population.
Table 5. Estimated Number of Opportunistic Infection Cases Averted Due to Antiretroviral Therapy, All Regions Combined
Opportunistic Infection No. of Cases Averted (95% CI)
Cost
Cost per Case, USD Total Savings, USD (95% CI)
Mycobacterium tuberculosis
Pulmonary 38 100 (3300–65 000) 182.76 7 000 000 (600 000–12 000 000)
Extrapulmonary 41 400 (4800–67 000) 234.99 9 700 000 (1 200 000–16 000 000)
Pneumocystis pneumonia 4850 (−20 000 to 24 000) 53.97 262 000 (−1 100 000 to 1 300 000)
Cryptococcal meningitis 1990 (−1900 to 5100) 301.00 599 000 (−560 000 to 1 500 000)
Cryptosporidium 21 100 (−1160 to 48 000) 6.65 140 000 (−7700 to 320 000)
Herpes simplex 1380 (−12 000 to 11 500) 3.16 4400 (−37 000 to 360 000)
Oral and esophageal candidiasis 34 800 (−3800 to 61 000) 3.65 127 000 (−14 000 to 225 000)
Cerebral toxoplasmosis 15 600 (−2100 to 29 000) NA
Bacterial pneumonia 18 800 (−94 000 to 102 000) NA
Total 161 300 (12 200–256 000) 17 700 000 (7 500 000–25 600 000)
For several opportunistic infections (OIs), the difference in incidence rate between antiretroviral therapy naïve and exposed was small relative to the uncertainty around each estimate, and so
CIs for cases and costs averted were very wide and included negative values. When all OIs are combined, this uncertainty is minimised and there is an overall positive effect on cases and costs
averted.
Abbreviations: CI, confidence interval; NA, no cost per case available; USD, US dollars.
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There was signiﬁcant heterogeneity with a very high I2 across
studies for all OIs. However, the limited data on potential
explanatory variables such as CD4 cell count or use of CTX
precluded any further analysis on key sources of heterogeneity.
Global Impact of ART Use on OIs Averted and Cost Savings
Based on difference in incidence for different OIs between ART-
naive and -exposed children, and assuming ART initiation in all
children meeting WHO 2010 treatment guidelines eligibility cri-
teria [17], ART was estimated to have potentially averted approx-
imately 161 000 (95% CI, 12 200–256 000) cases of OIs annually
(based on 2013 UNAIDS country estimates of number of HIV-
infected children), mainly in sub-Saharan Africa [3] (Table 5).
The majority of OIs averted were tuberculosis, candidiasis, and
Cryptosporidium diarrhea. For several OIs, the difference in inci-
dence rate between ART naïve and exposed was small relative to
the uncertainty around each estimate, and so CIs for cases and
costs averted were very wide and included negative values.
When all OIs are combined, this uncertainty is minimised and
there is an overall positive effect on cases and costs averted.
Total costs averted were $17 700 000 (95% CI, $7 500 000–
$25 900 000) annually, but these cost savings excluded bacterial
pneumonia, sepsis, cerebral toxoplasmosis, VZV, and cytomegalo-
virus, for which there were no accurate estimates of treatment costs
per case, and as such represent minimum cost savings. More than
90% of the savings came from averted cases of tuberculosis.
DISCUSSION
This systematic review and meta-analysis is the most comprehen-
sive assessment of the incidence and prevalence of the 14 most
important OIs and other infections and the effect of ART
among HIV-infected children in LMICs. It provides data from a
total of 55 679 children in 88 studies, of which 35 had data on in-
cidence, and 60 on prevalence. Our data highlight the high inci-
dence and burden of tuberculosis (approximately 30% for cTB,
PTB, and EPTB combined), bacterial pneumonia (25%), and can-
didiasis (8%)—the most common OIs in both ART-naive and ex-
posed children. This is similar to the pattern of OIs observed in a
companion meta-analysis we have conducted among adults [21].
Following ART initiation, the incidence for all OIs, except bac-
terial pneumonia, tuberculosis, candidiasis, and VZV declined to
<2.5%. The greatest effect of ART on incidence was for cerebral
toxoplasmosis, Cryptosporidium diarrhea, and EPTB. Statistically
signiﬁcant reduction (nonoverlapping CIs) in incidence was only
found for EPTB and reduction in prevalence was only signiﬁcant
for Cryptosporidium and bacteremia. These ﬁndings were also
similar to those reported in the adult meta-analysis [21].
In general, our results on incidence of OIs and magnitude of
effect of ART in LMICs are also consistent with meta-analyses
and cohorts from HICs [9–11, 22, 23], with the exception of
bacterial pneumonia, which remains very common among
ART-exposed children in LMICs. This is probably at least partly
accounted for by the high incidence of lower respiratory tract in-
fections in all children (regardless of HIV status) in LMICs [24].
Estimated minimum cost savings of approximately $17 mil-
lion from use of ART based on the 2010 WHO guidelines cri-
teria for ART initiation in children were considerable as there
was considerable imprecision in the estimates of number of
cases averted and in cost savings. In addition, this represents
an underestimate as several key OIs such as pneumonia were ex-
cluded from the cost analysis.
There are several methodological limitations to this analysis.
Overall, there was a paucity of well-described or large studies in
children relative to a comparable companion review in adults
(88 vs 126 eligible studies in adults, [21]), and the overall pooled
sample size was approximately a tenth that of the meta-analysis
in adults (55 679 children vs 491 000 in adult analysis, [21]),
leading to low reliability of individual estimates of incidence
of speciﬁc OIs and with wide and overlapping CIs between
ART naive and exposed. Few studies reported follow-up time,
which is crucial in analysis of incidence risks, and differences
in duration of follow-up may explain some of the observed dif-
ferences in incidence of speciﬁc OIs. Also, few studies reported
data on potentially important confounders of the impact of
ART, such as CD4 cell count, age at which ART was initiated,
and use of CTX prophylaxis. Overall, this precluded conduct of
a meta-regression that would have allowed us to examine con-
tributors to heterogeneity across studies and adjust for impor-
tant confounders. Interpretation of regional variation in
incidence and the effect of ART were limited by the few studies
from Asia, and Latin America and the Caribbean, resulting in
imprecise estimates in these regions. While our search was com-
prehensive, we cannot exclude the possibility of publication bias
in the studies reported. To limit this possibility, we searched
published abstracts and reviewed the gray literature for relevant
studies, neither of which yielded additional results.
There is also potential misclassiﬁcation of some opportunis-
tic and other infections due to limited diagnostic capacity in
many LMICs in addition to inherent difﬁculties in diagnosing
such infections in children. A signiﬁcant proportion of studies
failed to meet acceptable standards for the diagnosis of speciﬁc
OIs: <33% of incidence studies and <25% of prevalence studies
used an optimal diagnostic approach.
In summary, despite a more limited evidence base compared
to adults, this systematic review based on study data from a >20-
year period shows an overall trend of reduced incidence and
prevalence for most OIs after ART initiation, and the substan-
tial potential impact and cost savings on OIs averted with earlier
ART initiation. The recent publication of the landmark Strate-
gic Timing of Antiretroviral Therapy [25] and TEMPRANO
RCT [25, 26] results showed a major reduction in AIDS and
non-AIDS-related morbidity and mortality among adults with
early ART initiation above a CD4 count of 500 cells/µL. WHO
now recommends ART initiation regardless of CD4 count for
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adults [25]. Although these trials excluded children and adoles-
cents, the 2015WHO guidelines now also recommend ART ini-
tiation in all children and adolescents with a priority for those
aged <1 year to further simplify and promote more prompt and
ready access to ART among children [3, 27–33]. This is critical
as scale-up of ART has been less successful in children [3–5].
Strong mother–child prevention programs, expansion of access
to early infant diagnosis, and more robust procurement and sup-
ply management systems, including improved pediatric ART
formulation, are also critical to reducing the adult–pediatric
ART coverage gap, with an ultimate goal of eliminating the pedi-
atric HIV burden.
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Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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